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Abstract
Influenza is one of the most common diseases in the world and the cause for numerous deaths
every year. The primary method of combating the disease is the influenza vaccine, which is
produced by inoculating chicken eggs with inactivated virus. Some problems with this method
include allergic reactions to the chicken egg preparation, as well as the risk caused by exposure
to the phages present in the vaccine. An emerging solution is to use Self-Assembling Polypeptide
Nanoparticles (SAPN) to elicit an immune response in the body, rather than using inactivated
viruses. Both the C-terminus and N-terminus of the polypeptide can be modified, making the
construct an ideal platform for vaccine design. This project focuses on the synthesis, purification,
and refolding of two peptide constructs, BN5C and S43, which are specific protein sequences
that under the right conditions will refold into the 3-dimensional structures necessary for
producing an immune response. The BN5C construct proved difficult to purify. Thus, changes
were made for the S43 construct; notably, the addition of histidine tags to increase the efficiency
of purification. The size, shape, and homogeneity of the nanoparticles were tested using dynamic
light scattering and electron microscopy in order to determine the optimal refolding conditions
for the nanoparticles.
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Introduction

Influenza is an extremely prevalent disease and is the cause of many deaths every year.
The World Health Organization estimates that there are 25-30 million cases of influenza per year
in the United States alone. This number balloons up to 600 million cases per year when taking
the entire world into account. Influenza is a highly contagious disease that is spread by the
influenza virus, usually transferred from human to human. Influenza epidemics occur seasonally
and can affect up to 15% of the population [1]. The virus can also be transferred from animal to
human in some cases, as evidenced by avian influenza [2]. Viruses that are transferred from
animal to human are potentially more dangerous than the human variations, as the human
immune system is not familiar with these specific strains or how to combat them. Additionally,
the virus can also cause a worldwide pandemic, seen as recently as 2009, where a previously
unseen strain of the virus causes mass infections. The reason for influenza pandemics, which
have occurred many times throughout history, are mutation of the genes of the influenza virus;
specifically, the genes for the surface proteins, which makes it harder for the immune system to
fight the disease [2]. Some of the most dangerous influenza pandemics have been caused by
mutated avian influenza viruses that have adapted the ability to infect humans [1, 2].
The most effective way to combat the influenza virus continues to be vaccination [2, 3].
Currently, commercial influenza vaccines are made from inactivated influenza virus propagated
in embryonic chicken eggs [1]. However, there are several limitations to the current vaccination
options. Because vaccines are developed using chicken eggs, members of the population who
have allergies to eggs cannot use the vaccine. The constant mutation of the influenza virus means
that different strains circulate every year, and it becomes a challenge to manufacture vaccines
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quickly enough to make them readily available to the public [3, 4]. Furthermore, there are some
strains that cannot be propagated in eggs making it impossible to produce a vaccine [3].
Self-Assembling Polypeptide Nanoparticles (SAPN) offer a new method of creating
vaccines for many diseases. Nanoparticles have shown to be a viable solution to combat malaria
[5] and SARS [6], among others. Nanoparticles are known to be an effective adjuvant for
influenza vaccines [7, 8], and can be used to load antigens for an immune response [9]. One of
the distinctive features of the nanoparticles used in this study is that they form a repetitive
antigen display after self-assembly, promoting a strong immune response [6, 10]. Surface
proteins, or fragments of these proteins, for common pathogens, such as avian influenza, can be
engineered into the nanoparticle protein sequence to produce a specific immune response [10].
Various helper T-cell epitopes can be included in the structure of the nanoparticles for repetitive
display to boost immune responses.
Because the architecture of the peptide nanoparticles is similar to that of virus capsids,
they are able to generate an immune response with high efficiency while avoiding the use of
sometimes toxic adjuvants [10]. The peptide nanoparticles also solve many of the problems
involved with currently produced vaccines. Since the nanoparticles are peptide based, no
attenuated or inactive viruses are needed making them a safer and more stable option [11]. The
nanoparticles used in this study can be utilized in people who are allergic to eggs and can be
adapted to a wide variety of strains based on the epitopes incorporated into the protein sequence.
They are also able to be produced more cheaply and faster than traditional vaccines.
The BN5C-M2eN-mh-ch-8r construct and the S43-9C-2IAd-M2eN-ch construct are two
polypeptide nanoparticle constructs that were designed to elicit an immune response to avian
influenza. The BN5C construct is composed of a tetramer and a trimer connected by a linker
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region. Both ends of the construct contain B-cell epitopes. Near the N-terminus of the
polypeptide is an avian influenza epitope called M2e. The M2e epitope is based on the ectodomain of the influenza matrix protein 2 (M2), which is important in viral replication [12]. M2e
is highly conserved across strains of influenza and has not changed very much in the last century
making it an excellent epitope for an influenza vaccine [12]. The C-terminus of the construct
contains a cleavage peptide for the influenza surface protein hemagglutinin. The protein comes
in many different forms, but the H1 form was attached to the construct for this experiment. The
B-cell epitopes are included to trigger an immune response similar to an actual response to avian
influenza. The center of the construct contains an epitope for helper T-cells. The epitopes are not
specific to influenza but trigger a general immune response and contribute to viral elimination
and lung protection [13]. The epitope for helper T-cells is included to boost the overall immune
response.
Construct
BN5C

S43

Protein Sequence
MGSLLTEVETPTRNGWECKCSDSSGSLYRLTVIIDDRYESLKNLITLRADRLEMIINDN
VSTLRALLMGGRLLARLEELERRLEELARFVAAWTLKAAAVDLELAALRRRLEELARGP
GSIQSRGLFG
GSLLTEVETPTRNGWESKSSDSSGSLYRLTVIIDDRYESLKNLITLRADRLEMIINDNV
STILASITGGRLLLKLAELERRLEELERRLEYTSRAIQVVRARMEELERRLEELERRGH
HHHHH

Table 1. Protein sequences for the BN5C-M2eN-mh-ch-8r-H1 and S43-9C-2IAd-M2eN-ch
nanoparticle constructs. There are epitopes at both ends of the sequences and the S43 sequence
contains a his-tag for more efficient purification.
The S43 construct is very similar in that it is also composed of a tetramer and a trimer
connected by a linker region. The tetramer and trimer have a very similar sequence of amino
acids, respectively, as the BN5C sequence, but the linker region connecting them differs between
the two. Again, the construct contains an M2e epitope as well as a helper T-cell epitope. Besides
the linker region, the main difference between the S43 and BN5C constructs is that the S43
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construct contains a histidine tag (his-tag). The his-tag was included in order to make the protein
easier to purify due to the affinity of his-tags for Nickel-NTA resins.
The structure of the nanoparticle can change depending on the conditions that the protein
is placed in. The structure depends on the intra-molecular interactions of the protein, which
provide stability for the nanoparticle construct [14]. Both the BN5C and S43 constructs have a
coiled-coil structure that is an important part of the nanoparticle design. Notably, many of the
surface proteins of pathogens, including avian influenza, contain coiled-coil sequences [10],
which allow the nanoparticles to be easily modified to combat disease. Coiled-coil domains are
an extremely versatile structure motif and are responsible for structural stability and the refolding
capabilities of the nanoparticles [15]. The stability of the coiled-coils stems from the
hydrophobic interactions between the helices. However, in order to correctly form particles, the
intra-molecular interactions need to be maintained while avoiding interactions between separate
nanoparticles [10, 16].

Figure 1. A computer generated model of what the basic BN5C construct monomer (left) and
complete polypeptide nanoparticle (right) should look like. The tetramer and trimer, represented
in green and blue, assemble into coiled-coil structures in the fully assembled nanoparticle. The
B-cell epitope is represented in red.
The structure of the epitopes on correctly refolded nanoparticles is similar to those of
pathogen surface proteins [10]. Combined with the ability to modify the peptide sequences to
include epitopes for avian influenza, the characteristics of SAPNs create an ideal formula for a
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new type of vaccine. The nanoparticles could induce a strong immune response without the
drawbacks of current influenza vaccines, such as the inclusion of attenuated viruses, slow
production, and inability to combat multiple strains. Here, the biophysical properties of the
nanoparticles were assessed to determine the optimal refolding conditions.
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Methods and Materials

Generation of Recombinant Cells
An oligonucleotide sequence was designed for the BN5C-M2eN-mh-ch-8r-H1 construct
that contained the nucleotides needed to code for the H1 hemagglutinin cleavage peptide, as well
as nucleotides on either side of the DNA coding for the peptide that could be recognized by the
Xma I and Eco RI restriction enzymes. The restriction sites recognized by these enzymes are
CCCGGG and GAATTC, respectively. The oligonucleotides were ordered from Integrated DNA
Technologies and arrived as separate forward and reverse strands. Both the forward and reverse
strands were brought to a concentration of 0.100 μg/mL. The annealing of the oligos was carried
out in a micro-centrifuge (microfuge) tube by mixing 2 μL each of the forward and reverse
strands, 10 uL 10X STE and 34 uL sterile distilled water and placing in a heat block, Fisher
Scientific Isotemp Model 125D, for 90 seconds at 95°C and then cooling at room temperature. A
2% agarose gel was run in order to ensure the successful annealing of the forward and reverse
strands.
5’
3’

CCGGGGTCCAGGTAGTATACAAAGTAGAGGATTATTTGGATAATG
CCAGGTCCATCATATGTTTCATCTCCTAATAAACCTATTACTTAA

3’
5’

Figure 2. The annealed forward and reverse strands of the oligonucleotide. The overhangs on the
5’ ends of the strands enable the insertion of the oligo into the plasmid for the BN5C construct
following double digestion.
The plasmid, which codes for the BN5C construct, was double digested with Eco RI and
Xma I restriction enzymes by combining 20 μL plasmid with 5 μL 10X Buffer 4, 5 μL 10X BSA,
and 1 μL each of Eco RI and Xma I enzyme. The mixture was incubated at 37°C for 3 hours to
carry out the reaction. The mixture was purified using a Qiagen purification kit, assuming an
80% recovery of the plasmid. The cleaved ends of the plasmid were then dephosphorylated by
12

combining 28 μL of the double digested plasmid with 5 μL 10X AP reaction buffer, 1.2 μL
Antarctic Phosphatase and 15.8 μL distilled water and incubated at 37°C for 30 minutes. The
enzyme was then deactivated by incubating at 65°C for 5 minutes. The ligation of the plasmid
and insert occurs most efficiently at a plasmid to insert ratio of 1 to 3, modified by the ratio of
their lengths in kb. Based on their concentrations, 4 μL plasmid and 3.56 μL insert were
combined with 0.5 μL of distilled water and incubated at 45°C for 5 minutes. A microfuge tube
containing 1.1 μL plasmid and 6.9 μL distilled water was used as a control. The mixtures were
then cooled on ice while 1 μL reaction buffer and 1 μL ligase were added to each and the ligation
mixtures were incubated at 16°C and 1000 rpm overnight. This was achieved by placing an
Eppendorf Thermomixer Shaker, Model EF4283A, in the 4°C refrigerator. The ligated samples
were then stored at -20°C.
Three 100 μL samples of aliquoted Escheria Coli (E. Coli) DH5α strain cells were taken
from the -80°C freezer and thawed on ice for transformation. The DH5α strain of E. Coli was
used because this strain has a high efficiency for transformation and is useful in maintaining
plasmids [17]. While on ice, 5 μL of the ligated plasmid and insert was added to one of the
samples, 5 μL of the plasmid control was added to the second, and the third was left as a negative
control. All of the samples were left on ice for 30 minutes, and then heat shocked for 90 seconds
at 42°C in the heat block. The samples were then put back on ice. After two minutes, 800 μL of
SOC medium was added to help with growth of the cells. The three samples were then incubated
at 37°C for 45 minutes in the thermomixer. After removal from the thermomixer, 100 μL of each
sample was spread onto an LB-Agar plate containing 100 mg/mL ampicillin, which was inverted
and incubated at 37°C overnight.
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After confirming no growth on either of the controls and growth on that plate containing
the ligated plasmid and insert, 4 isolated colonies were scraped from the agar plate and mixed
with four separate tubes of 5 mL Luria Bertani (LB) broth to be incubated overnight at 37°C and
180 rpm in the shaker, New Brunswick Scientific C25 Floor Model. The samples were then
centrifuged at 4000 rpm in the Beckman Coulter Avanti Centrifuge J-20 XP. The supernatant
was removed and the pellet was resuspended in 600 μL sterile distilled water. The Promega
Plasmid Miniprep System was used to extract the plasmid DNA from the samples, which was
sent for DNA sequencing to ensure the ligation had taken place and the samples had the proper
sequence.
The process for the S43-9C-2IAd-M2eN construct was slightly different because the
construct genes arrived from GenScript in the Puc57 vector, which is not an expressing vector.
Therefore it needed to be cloned into a vector that could express the protein, the pPEP-T vector.
Sections from the Puc57 vector and pPEP-T vector needed to be combined to create a plasmid
that would code for the S43 protein. A technique called sub-cloning was used to extract the
needed sections from both plasmids. Each plasmid was double digested, separately, with Eco RI
and Nco I. For the pPEP-T vector, 10.6 μL plasmid, 5 μL 10X Buffer 4, 5μL 10X BSA, and 32.4
μL distilled water were mixed in a microfuge tube. In another microfuge tube, 16.2 μL Puc57
plasmid, 5 μL 10X Buffer 4, 5 μL 10X BSA, and 21.8 μL distilled water were mixed. Each of the
tubes had 1 μL each of Eco RI and Nco I restriction enzymes added to them and the mixtures
were incubated at 37°C for 4 hours. Following the reaction, 30 μL of each sample was combined
with 6 μL loading buffer, loaded into a 2% agarose gel, and run at 80 V for 80 minutes. The gel
was visualized on a Safe Imager (Invirogen) and the sections containing the desired fragments
were cut out using razor blades. The larger fragment of the pPEP-T and the smaller fragment of
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the Puc57 were removed and placed into separate microfuge tubes. The Qiagen Gel Extraction
Kit was used to extract the plasmid from the small cut-outs of gel and the concentrations were
recorded.
The pPEP-T fragment was considered the plasmid and the Puc57 fragment was
considered the insert for the ligation. The insert needed to be dephosphorylated, which was
carried out in the same manner as the BN5C construct. Again, a plasmid to insert ratio of 1 to 3
is the most efficient for ligation, depending on their lengths in kb. In a microfuge tube, 3.57 μL
vector plasmid and 1.86 μL insert (a 1:10 dilution of the insert) were mixed with 1 μL reaction
buffer, 1 μL ligase, and 2.57 μL distilled water. A control, composed of 1.1 μL plasmid, 1 μL
reaction buffer, 1 μL ligase, and 6.9 μL distilled water, was mixed in a separate microfuge tube.
The transformation into E. Coli DH5α cells was done the same way as the BN5C sequence. A
sample of the plasmid was sent for DNA sequencing to ensure the plasmid had the correct
sequence.

Production of Protein
Two 100 μL samples of aliquoted E. Coli BL21 strains were removed from the -80°C
freezer and thawed on ice. The BL21 strain of E. Coli was used because this strain has a high
level of gene expression and is very efficient for expressing a target protein. The BL21
chromosome contains the bacteriophage T7 polymerase gene that targets the T7 promoter located
in the expression vectors that contain the genes of interest [17]. One of the samples was
inoculated with 5 μL of plasmid coding for the BN5C-H1 protein confirmed to have the correct
sequence and the other sample was used as a control. Both were left on ice for 30 minutes and
then heat shocked for 90 seconds at 42°C in the heat block. After returning to ice for 2 minutes,
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800 μL SOC medium was added to each to promote recovery and growth. The samples were then
incubated at 37°C and 1000 rpm in a thermomixer for 45 minutes. After incubation, 100 μL from
each sample were spread on separate LB-Agar plates with 100 mg/mL ampicillin and the plates
were inverted and incubated at 37°C overnight. The plates were checked the next day for growth
and an isolated colony from the plate containing the plasmid sample was scraped and used to
inoculate 40 mL of LB broth. The LB broth with 100 mg/mL ampicillin was incubated overnight
at 37°C and 180 rpm in the shaker.
Three liters of LB broth were made, split into three separate flasks for better aeration and
growth. The flasks were placed in the shaker and 1 mL of ampicillin was added to each. Each of
the flasks was inoculated with 10 mL of the overnight culture created from the BL21 plate. The
remaining 10 mL from the overnight culture was used to create glycerol stocks of 750 μL culture
and 250 μL sterile 20% glycerol that were placed in the -80°C freezer for future use, if needed.
The three flasks of LB broth were kept in the shaker at 37°C and 180 rpm and their growth was
monitored using a spectrophotometer (biowave S2100 Diode Array Spectrophotometer). A
random sample of LB broth was taken at the start to use as a blank and the absorbance of one of
the flasks was measured every 30 minutes. When the absorbance at 600 nm (A600) reached
between 0.5 and 0.6, the cultures were induced by adding 1 ml of 0.8 M Isopropyl-β-Dthiogalactopyranoside (IPTG) to each flask. IPTG induces the production of the target protein by
the E. Coli BL21 cells. The flasks were then incubated in the shaker at 37°C and 180 rpm for 4
hours.
After incubation, each of the three flasks of LB broth were transferred into 1 L centrifuge
tubes and centrifuged at 4000 g for 15 minutes. The supernatant was removed and the cell pellets
at the bottom of each tube were combined in a 50 mL falcon tube. The weight of the combined
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cell pellets was taken and the tube was stored at -20°C. The process was the exact same for
producing the protein for the S43 construct.

Purification of the Protein
Approximately 4.5 grams of the BN5C-H1 protein was thawed on ice and resuspended in
20 mL of cold Cracking Buffer (20 mM citrate pH 6, 150 mM NaCl, 0.2% cholate, 5 mM
EDTA). The falcon tube containing the protein in Cracking Buffer was placed in the sonicator,
Masonix Sonicator 3000, suspended in an ice water bath to keep the sample cold during
sonication. The protein/buffer was sonicated at power level 5-6 for 5 minutes, alternating 4
seconds on and 6 seconds off. The falcon tube was then centrifuged at 8000 rpm for 15 minutes.
The supernatant was removed and placed in a falcon tube for analysis (Wash 1). The pellet was
resuspended in 20 mL of Cracking Buffer by pipetting and vortexing. It was again centrifuged at
8000 rpm for 15 minutes and the supernatant was set aside (Wash 2). The pellet was then
resuspended in 20 mL of Wash Buffer (20 mM citrate pH 6, 150 mM NaCl) and centrifuged at
8000 rpm for 15 minutes. The supernatant was removed and set aside (Wash 3). The pellet was
resuspended in 25 mL of Wash Buffer and the process was repeated (Wash 4). Then, the pellet
was resuspended in 20 mL of Inclusion Body Dissolving Buffer (20 mM citrate pH 3.5, 9 M
urea, 0.3 mM TCEP). It was sonicated again, this time at power level 6.5 for 6 minutes,
alternating between 4 seconds on and 6 seconds off. This was followed by centrifuging at 12,000
rpm for 15 minutes. The supernatant was removed and set aside (Wash 5) and the pellet was
resuspended in 4 mL Inclusion Body Dissolving Buffer. All of the samples were run through
Sodium Dodecyl Sulfate Polyacrylamide gel electrophoresis (SDS-PAGE) to test for the
presence of protein. This was done by mixing 7 μL of each sample with 7 μL of SDS-PAGE
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buffer and heating at 95°C for 5 minutes in the heat block. Then each sample was run through a
polyacrylamide gel first for 15 minutes at 70 V, then at 180 V until the sample reached the
bottom of the gel. The gel was submerged in Coomassie Blue (2.5 g brilliant blue, 40% distilled
water, 50% ethanol, 10% glacial acetic acid) for 2 hours on a rotator (Lab-line MAXI Rotator
Mixer Model 4631) and then rinsed in de-staining solution (15% methanol, 10% acetic acid).
The gel was examined for the presence of protein.
The next step of purification required an ion exchange column which was created by
using a syringe to insert 8 mL of SP-sepharose resin (Qiagen) into a column with a closed
stopcock. Using the syringe to push the slurry into the bottom of the column minimized bubbles.
The column was allowed to settle and was then equilibrated with 80 mL Inclusion Body
Dissolving Buffer. The samples from the previous step that showed evidence of the presence of
protein were combined and passed through the column and the flow through was collected. The
column was then was washed with 80 mL Inclusion Body Dissolving Buffer and the flow
through was collected. A salt gradient was used to elute the protein from the column. Each
gradient step was 40 mL and the first 20 mL were collected in 2 mL fractions. The steps in the
gradient were as follows: 0 M NaCl, 50 mM NaCl, 100 mM NaCl, 250 mM NaCl, 500 mM
NaCl, and 1 M NaCl (20 mM citrate pH 3.5, 9 M urea, 0.3 mM TCEP). Finally, an elution buffer
with pH 8.5 was passed through the column and ten 2 mL fractions were collected. The fractions
were checked for the presence of the protein of interest by recording their optical density at 280
nm (OD280) in the spectrophotometer. Those fractions with high values for OD280 were analyzed
by SDS-PAGE. The fractions that tested positive for the protein were combined and dialyzed
into 20 mM Tris pH 7, 5 % glycerol because of the corrosive effects of remaining in urea
solution for too long. A strip of dialysis tubing was cut and equilibrated first in heavy metals
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cleaning solution, and then the Tris pH 7.5 buffer. The dialysis tubing was filled with the protein
in urea solution, clipped on both ends, and submerged in the urea-free buffer overnight.
The protein then underwent purification through a Q-sepharose column for the removal
of endotoxin. The protein was dialyzed into a urea buffer (20 mM CAPS pH 10.5, 9 M urea, 0.3
mM TCEP) for denaturation. This time, 8 mL of Q sepharose resin (Qiagen) was pumped into
the bottom of the column via syringe and allowed to settle. The column was equilibrated with the
dialysis buffer and then the sample containing the protein was passed through the column.
Fractions were collected as above, first of the urea buffer mentioned above (20 mM CAPS pH
10.5, 9 M urea, 0.3 mM TCEP), followed by a gradient of a lower pH buffer (20 mM Tris pH
7.5, 9 M urea, 0.3 mM TCEP) with the following steps: 0 M NaCl, 50 mM NaCl, 100 mM NaCl,
500 mM NaCl, 1 M NaCl. The OD280 of each fraction was measured and those with high values
were tested using SDS-PAGE. The fractions that tested positive for the presence of the protein
were collected and dialyzed into the same urea-free buffer as above (20 mM Tris pH 7, 5 %
glycerol). Another Q-sepharose column was run with a smaller gradient to further purify the
protein. All of the steps and buffers were the same, except the gradient was as follows: pH 10.5,
pH 7.5 0 M NaCl, 100 mM NaCl, 200 mM NaCl, 300 mM NaCl, 400 mM NaCl, 500 mM NaCl,
1 M NaCl. They were again collected in 2 mL fractions, with the exception of the 1 M NaCl,
which was collected as a whole in a 50 mL falcon tube. Again, the OD280 of the samples were
tested, and those with high values were run through a SDS-PAGE.
The purification for the S43 construct was much different, due to the presence of a
histidine tag (his-tag) within the protein. The his-tag meant that the protein could be purified
more efficiently via a Nickel affinity column. The cell pellet obtained via centrifugation was
resuspended in three times its weight of Lysis Buffer (9 M urea, 10 mM Tris pH 8, 100 mM
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NaH2PO4, 20 mM imidazole). The falcon tube was suspended in a bucket of ice water and
sonicated at power level 5, for 5 minutes alternating 4 seconds on, 6 seconds off. The sonicated
cells were then centrifuged at 30,600 g for 45 minutes. The supernatant, referred to as the lysate,
was removed and the debris pellet was discarded. The Nickel column was created by pipetting 4
mL of Ni-NTA slurry from Qiagen into a 15 mL falcon tube. The slurry was centrifuged at 4000
rpm for 3 minutes. The supernatant (ethanol) was removed and 3 mL of lysis buffer was added to
the falcon tube to wash the beads. The mixture was then centrifuged at 4000 rpm for 3 minutes.
The lysis buffer was removed by pipette and the Ni-NTA slurry and cell lysate were combined in
a 50 mL falcon tube. The tube was mixed gently via a rotator mixer, Lab-line MAXI Rotator
Mixer Model 4631, at power level 4 overnight.
The Ni-NTA/lysate mixture was poured into a closed column and allowed to settle for
several minutes. The stopcock was opened and the flow through was collected for analysis. The
column was then washed with 80 mL of Lysis Buffer, which was also collected. Then, 50 mL of
Phosphate Buffer (8 M urea, 10 mM Tris pH 8, 500 mM H2PO4, 20 mM imidazole) was run
through the column and collected in a falcon tube. The next step was to run a pH gradient
through the column. The pH Buffer (9 M urea, 20 mM citrate, 100 NaH2PO4, 20 mM imidazole)
was split into three 50 mL fractions that were equilibrated to pH 6.3, pH 5.9, and pH 4.3. The
buffers were run through the column in that order and collected for analysis. An elution buffer (8
M urea, 10 mm Tris pH 8, 100 NaH2PO4) was used to create an imidazole gradient to run
through the column. The gradient was as follows: 100 mM imidazole, 250 mM imidazole, 500
mM imidazole, 1 M imidazole. For the gradient, 30 mL of each imidazole concentration was run
through the column and collected in 2 mL fractions. The OD280 for the fractions from the
imidazole gradient were read and the peaks from each step in the gradient were analyzed by
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SDS-PAGE along with samples from each of the buffers passed through the column and the flow
through. The samples that appeared to contain the protein of interest were combined and
dialyzed into Imidazole Free Buffer (8 M urea, 20 mM Tris pH 7.5, 150 mM NaCl, 2 mM
EDTA) overnight, using the same process as above, then into 0 M urea to protect against the
corrosive effect of urea on proteins. The sample was divided into four falcon tubes and frozen at
-80°C.

Self-Assembly of the Nanoparticles
After collection of reasonably pure protein, the refolding and self-assembly of the BN5CM2eN-mh-ch-8r-H1 nanoparticles was attempted by dialyzing the protein into different buffer
conditions. The concentration of the protein in solution was estimated, and it was concluded that
refolding should be done at the concentration at which the protein was purified. The dialysis was
done as above, with the dialysis tubing equilibrated first in heavy metals cleaning solution, then a
small quantity of the target buffer before adding the protein and dialyzing it overnight in said
buffer. The refolding process that was used is called “direct refolding” which requires that the
protein first undergo dialysis into an 8 M urea variation of each buffer, followed by a 0 M urea
concentration. The 8 M urea buffers were kept at room temperature, while the 0 M urea buffers
were kept at 4°C. The protein was filtered to remove impurities during the switch from 8 M urea
buffer to 0 M urea buffer. The first attempt at refolding was done with a buffer of 20 mM Tris
pH 8.5, 150 mM NaCl, 5 % glycerol (first dialyzed into 8 M urea, then 0 M urea) to get an idea
of the general characteristics of the construct under these conditions. A sample of protein was
taken for analysis with Dynamic Light Scattering (DLS) and electron microscopy. Then, the
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protein was split into six equal samples and refolding was attempted under the following
conditions:
A) 20 mM Citrate pH 6, 150 mM NaCl, 5% glycerol
B) 20 mM Tris pH 8.5, 150 mM NaCl, 5% glycerol, 0.1 mM TCEP
C) 20 mM CAPS pH 10.5, 150 mM NaCl, 5% glycerol
D) 20 mM Tris pH 8.5, 300 mM NaCl, 5% glycerol
E) 20 mM Tris pH 8.5, 0 M NaCl, 5% glycerol
F) 20 mM Tris pH 8.5, 150 mM NaCl, 5% glycerol, 0.1% sodium deoxycholate

As above, the refolding process required that for each condition the protein was first
dialyzed into 8 M urea buffer at room temperature overnight, then transferred into a urea-free
buffer for that condition, and dialyzed overnight at 4°C. A sample of protein was taken from
each condition and analyzed using Dynamic Light Scattering (DLS), Malvern Zetasizer S Model,
to examine the size, aggregation, and dispersion of the particles that had formed. Samples were
then taken from each condition and further examined using Transmission Electron Microscopy
(TEM) to visualize the nanoparticles. After analyzing the results from the DLS machine and
TEM, a new set of conditions in which to test refolding of the nanoparticles was created. The
second set of conditions was as follows:
A) 20 mM Tris pH 8.5, 0 M NaCl, 5% glycerol
B) 20 mM Tris pH 8.5, 150 mM NaCl, 5% glycerol, 0.1% sodium deoxycholate
C) 20 mM Tris pH 8.5, 150 mM NaCl, 5% glycerol, 0.2% sodium cholate
D) 20 mM Tris pH 8.5, 0 M NaCl, 5 % glycerol, 0.1% sodium deoxycholate
E) 20 mM Tris pH 8.5, 0 M NaCl, 5% glycerol, 0.2% sodium cholate
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F) 20 mM Tris pH 8.5, 50 mM NaCl, 5% glycerol

Again, the refolding process required that for each condition the protein was first
dialyzed into 8 M urea buffer at room temperature overnight, then transferred into a urea-free
buffer for that condition, and dialyzed overnight at 4°C. Samples were taken from each condition
and analyzed using the DLS machine and were also examined using TEM to visualize the
nanoparticles.
A different method called “quick refolding” was implemented to test the refolding
conditions for the S43-9C-2IAd-M2eN construct. A small amount of the protein was thawed at
4°C and denatured by dialyzing it into urea buffer (9 M urea, 20 mM Tris pH 7.5, 150 mM NaCl,
5 % glycerol). The protein was then filtered to remove impurities and brought to a concentration
of 1.0 mg/mL. 150 μL of the protein was added drop-wise to 2.85 mL of buffer for each
refolding condition to obtain a final concentration of 0.05 mg/mL. The protein was added while
the buffer was spinning extremely fast to ensure proper mixing of the protein in the buffer. The 3
mL total of protein and buffer was pipetted into dialysis tubing and placed in a beaker containing
that buffer overnight at 4°C. The first type of condition to be tested was an ammonium sulfate
buffer (20 mM Tris pH 7.5, 20 mM (NH4)2SO4, 5% glycerol and 20 mM Tris pH 7.5, 50 mM
(NH4)2SO4, 5% glycerol). The results from the quick refolding were analyzed using DLS and
electron microscopy. A new set of conditions were designed to further test the refolding of the
S43 construct, as follows:
A) 20 mM Tris pH 7.5, 50 mM NaCl, 5 % glycerol
B) 20 mM Tris pH 7.5, 150 mM NaCl, 5% glycerol
C) 20 mM Tris pH 8.5, 150 mM NaCl, 5% glycerol

23

The samples were removed from dialysis tubing and pipetted into falcon tubes. Samples
were taken for each condition to analyze using DLS and electron microscopy. Based on the
results from the first set, a second set of refolding conditions was designed. Quick refolding was
used again for the second set, however this time 250 μL of protein was refolded in 4.75 mL of
filtered buffer, for a final volume of 5 mL. Again, the starting and final concentration of the
protein was 1.0 mg/mL and 0.05 mg/mL respectively. The second set of conditions was as
follows:
A) 20 mM Tris pH 7.5, 5 % glycerol
B) 20 mM Tris pH 7.5, 100 mM NaCl, 5% glycerol
C) 20 mM Tris pH 7.5, 50 mM NaCl, 5% glycerol, 0.2% sodium cholate
D) 20 mM Tris pH 7.5, 50 mM NaCl, 5% glycerol, 0.1% sodium deoxycholate

Following the refolding, samples were taken from each condition and analyzed using DLS, as
well as TEM to visualize the nanoparticles.
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Results

Protein Purification
SDS-PAGE was used to test for the presence of protein throughout the process of protein
purification. The BN5C-M2eN-mh-ch-8r monomer has a molecular weight of 14.39 kDa but
there could be cases where the protein forms a dimer or trimer, in which case the molecular
weight would be double or triple that value, respectively. Normally, these bonds would be
disassociated by SDS, but the coiled-coil interactions and di-sulfide bonds are very strong and
SDS does not fully disrupt them. Therefore, when examining the gels, a band at the level
corresponding to those values on the molecular weight marker could still indicate the protein of
interest. Since the buffers that were used in the purification contain urea, which denatures
proteins, it is more likely that we will find evidence of the monomer via a band at 14.39 kDa.
The first gel examined the results of the inclusion body preparation that immediately
followed the lysing of the cells via sonication. The successive supernatants of the centrifugation
(Washes 1-5) were tested along with a sample from the pellet, which had been dissolved in
Inclusion Body Dissolving Buffer. It was anticipated that the protein would most likely be
present in the fifth wash (Supernatant 5), and possibly the pellet as well. The fifth supernatant
was a result of sonicating the pellet in Inclusion Body Dissolving Buffer and centrifuging at
12,000 rpm for 15 minutes. The results confirmed this, however the protein was left in urea
solution for too long and it was believed that it was no longer usable for refolding. The process
was restarted by again growing three 1 L cultures, combining the cell pellets, and sonicating in
Cracking Buffer and Inclusion Body Dissolving Buffer. This time however, after the fifth
centrifugation the pellet was resuspended in 2 mL Inclusion Body Dissolving Buffer so that the
protein would be more concentrated.
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Figure 3. SDS-PAGE from inclusion body purification. The far left well is a molecular weight
marker and the other wells are marked Wash 1 through 5, the resulting supernatants from
centrifugation during the purification, and the resuspended cell debris pellet. The darkest bands
in the Wash 5 and Pellet lanes fall between 10 and 15 kDa and confirm the presence of the
protein of interest.
The gel was run once again with samples from each wash (supernatant) and the pellet.
Again, it was expected that the BN5C-M2eN-mh-ch-8r-H1 protein would be present in Wash 5
as well as the pellet. The result is shown in Figure 3. The protein of interest has a molecular
weight of 14.39 kDa so it would be represented by a band level with the space between the
markers for 10 kDa and 15 kDa. The dark bands present at this level in the lanes for Wash 5 and
the pellet show that the protein is present in both of these samples. Since the bands at this level
are the darkest, the protein of interest is the most abundant protein in these washes. There are
several lighter bands present in both lanes as well, indicating other contaminants. The protein is
not very pure, but since this is only the first step of purification that is to be expected. Washes 3
and 4 also show faint bands at the correct weight, but they are very light, which indicates that
there is very little of the protein contained in these samples. Thus, it would not be worthwhile to
dilute the collection of protein at this level by adding the volumes of these washes if there is only

26

going to be a small gain in the amount of protein. Wash 5 and the pellet suspended in I.B.
Dissolving Buffer were combined into a 50 mL falcon tube for the next step in the purification.
The SP-sepharose gel was set up and infused with the protein, then extracted with a NaCl
gradient (50 mM, 100 mM, 250 mM, 500 mM, and 1 M) followed by a pH 8.5 buffer. The
samples were collected in 2 mL fractions, ten for each buffer. The optical density of the samples
at 280 nm (OD280) was read using a spectrophotometer and used to determine which fractions
should undergo further analysis using gel electrophoresis. The lower concentrations of salt, 50
mM and 100 mM, all had OD280 readings under 0.1, indicating that there was not much protein in
the sample. Starting with the 250 mM NaCl gradient, the OD280 readings began to increase in
value. Generally, values that had an OD280 greater than 1.0 were believed to contain a significant
amount of protein and samples from these sets of fractions were analyzed via SDS-PAGE. There
was at least one sample from each of the 250 mM, 500 mM, 1 M, and pH 10.5 gradients used in
the gel electrophoresis.

Figure 4. SDS-PAGE of fractions from SP-sepharose column purification. The far left column
contains a molecular weight marker. The numbers below the buffer labels indicate the fraction
the sample was taken from. The dark bands in the two fractions from the pH 8.5 represent the
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presence of the protein of interest. The lighter bands at higher molecular weights may be the
dimer and trimer of the protein.
Samples from fractions with high OD280 readings were run in the gel. The fifth fraction
from the 500 mM NaCl buffer had an extremely high OD280 that was greater than 2.0 and thus
unable to be read accurately by the spectrophotometer. The result is shown in Figure 4. The
majority of the lanes show many bands at different heights, and none of the bands are very dark,
indicating that there was not a large amount of protein. However, the two lanes containing
samples from the pH 8.5 wash had dark bands slightly below the 15 kDa band in the molecular
weight marker, which matches with the known size of the BN5C construct, 14.39 kDa. The
bands are darker than any of the other bands on the gel and are by far the darkest in their
respective lanes, showing that the protein of interest is more pure in these samples. There are
lighter bands at higher molecular weights in these lanes but they match up with the molecular
weights of the dimer and trimer of the BN5C construct, which were calculated to be 28.78 kDa
and 43.17 kDa, respectively. These bands could be due to coiled-coil trimer formation or
disulfide bond formation, which are strong enough to not be fully disrupted by SDS. There is a
band just underneath the band representing the monomer of the protein in the sample for the
ninth fraction of the pH 8.5 wash, but these are still the purest samples and the SP-sepharose
column is only the second of three purifications. The fourth through tenth fractions from this
wash had the highest OD280 readings and these seven fractions were combined in a 50 mL falcon
tube in preparation for the next step of purification.
The next step in the purification for the BN5C construct was a Q-sepharose column. The
OD280 for each of the fractions were read to estimate the amount of protein present. The values
for the pH 10.5, 0 M NaCl, 100 mM NaCl, and 1 M NaCl fractions were essentially 0, but some
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of the 500 mM fractions did have relatively high readings. However, the values were all under
1.0, much lower than the OD280 readings taken from the SP-sepharose column.

Figure 5. SDS-PAGE from Q-sepharose column purification. The far right lane contains a
molecular weight marker. The only lanes that have visible bands are those with samples from the
500 mM NaCl wash. The fractions appear to co-elute. There also appears to be a band below the
band associated with the monomer of the protein, which could represent impurities.
Samples from the fractions with the highest OD280 values from each wash were taken for
further examination using SDS-PAGE. The results are shown in Figure 5. The only visible bands
are in lanes that correspond to fractions from the 500 mM NaCl wash. The samples appear to
completely co-elute, and while it is possible that all of the bands represent the protein of interest,
it is not likely. Furthermore, in all three lanes of the 500 mM NaCl wash there is a band beneath
the band which corresponds to the protein of interest. This appears to be some sort of
contamination which means that the protein is not pure and will make the refolding step more
difficult. There was a large step in the gradient from 100 mM NaCl to 500 mM NaCl and smaller
gradient steps could yield a purer protein. Creating more steps in the gradient would at least
create a clearer image of how the protein was purifying.
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The Q-sepharose column was repeated with a smaller gradient. The OD280 readings for all
of the fractions from the purification were extremely low. With the exception of a few fractions
from the 200 mM NaCl and 300 mM NaCl gradients, the values were all essentially 0.

Figure 6. SDS-PAGE from second Q-sepharose purification. The far left lane contains a
molecular weight marker. Bands appear in the 200 mM and 300 mM lanes, but are very faint.
Again the samples seem to co-elute and there are bands visible beneath those that correspond to
the protein of interest.
Samples from each of the washes as well as the flow through were used for SDS-PAGE
analysis. The result is shown in Figure 6. The bands are much fainter than they were in the
previous Q-column gel. The bands are in similar order to the previous gel, and it appears that the
second column purification did not result in purer protein. In addition, the fractions still appear to
co-elute, which is a positive sign in terms of the bands representing the protein that we are
looking for. While the protein does not seem to be very pure and much of it was lost during the
many rounds of purification, the only step to take at this point is to attempt to refold the
construct. The fractions from the 200 mM NaCl and 300 mM NaCl washes were combined and
filtered. Using the absorbance at 280 nm (A280) it was estimated that the concentration of the
protein was about 0.05 mg/mL. The refolding of the protein was attempted at this concentration.
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The purification for the S43-9C-2IAd-M2eN construct was much simpler due to the histag contained in the protein. Thus, only one gel was run.. The S43 construct has a molecular
weight of 14.19 kDa, so bands in the gel that represent the monomer of this protein will still be
slightly below the 15 kDa molecular weight marker. Again, it is possible that the dimer or trimer
of the protein could appear in the gels, but since the purification was done in urea buffer this is
less likely and the monomer will appear more readily.
The his-tag in the construct enables the construct to bind very efficiently to the nickel
beads in the Ni-NTA column. It was assumed that the protein would elute with the pH 5.9 and
pH 4.3 washes. The OD280 of the imidazole fractions were measured using the spectrophotometer
to find the peaks from each wash. The peak of each wash in the imidazole gradient represents the
fraction most likely to contain the protein of interest.

Figure 7. SDS-PAGE from Ni-NTA column purification. The far left lane contains a molecular
weight marker. The extremely bright band in the pH 4.3 wash indicates a large amount of protein
present. The band matches the molecular weight of the desired protein and there are no other
visible bands. There is also a faint band at the same height in the pH 5.9 wash.
A sample of the fraction from each step in the imidazole gradient with the highest OD280
was analyzed via SDS-PAGE along with samples from the flow through, lysis buffer wash,
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phosphate buffer wash, and each pH wash. The results are shown in Figure 7. The large dark
band in the lane for the pH 4.3 sample shows the presence of the protein of interest. The height
of the band matches the molecular weight for the S43 construct, 14.19 kDa. There is a very faint
band below this, which may indicate a small amount of impurity. The faint bands in the pH 6.3
and 5.9 washes are at the same level and are likely also evidence of the protein of interest. These
are the only three clear discernable bands on the entire gel. The band in the pH 4.3 wash is very
dark, indicating that there is a lot of protein present, and it appears to be quite pure as well. The
lighter bands from the samples of the other two pH washes are very light, and although they also
seem to be pure, it is not worth diluting the concentration of the protein by combining these
washes with the pH 4.3 wash.

Dynamic Light Scattering Reports

Figure 8. DLS report for first refolding attempt of BN5C-M2eN-mh-ch-8r-H1 construct. The
first refolding attempt was done using a buffer containing 20 mM Tris at pH 8.5, 150 mM NaCl
and 5% glycerol. There is not much agreement in size distribution.
Dynamic Light Scattering (DLS) reports are used to analyze the assembled nanoparticles
with respect to size, aggregation, and dispersion of particles. The goal of refolding is to achieve
nanoparticles that are uniform in size and shape. Ideally, the graph would be very narrow and tall
with the peak at the correct size in diameter for the construct. It is expected that the correctly
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refolded nanoparticles will be about 25-35 nanometers in diameter. Throughout the refolding
process of the BN5C-H1 construct, the protein being refolded had a very low concentration. A
baseline condition for BN5C-M2eN-mh-ch-8r-H1 was analyzed using DLS. The results are
shown in Figure 8. The DLS report indicates the sample is poly-dispersed, as there is no
agreement in the size of the particles. There is no evidence of uniformity among the particles as
none of the sample runs match with each other, and there are several peaks visible within each
run. The report indicates that the particles are not the correct size and the sample was not
homogeneous. The peaks at higher molecular weight could be due to aggregation of the protein
or incorrect formation of the nanoparticles. Despite the poor results, TEM images of particles
from this refolding condition were still taken. Since these results did not give us positive
refolding results, the next refolding attempt had a very wide range of conditions.

A
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B

D
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Figure 9. (A) DLS report of BN5C construct refolded in 20 mM Citrate pH 6, 150 mM NaCl,
5% glycerol. (B) DLS report of BN5C construct refolded in 20 mM Tris pH 8.5, 150 mM NaCl,
5% glycerol, 0.1 mM TCEP. (C) DLS report of BN5C construct refolded in 20 mM CAPS pH
10.5, 150 mM NaCl, 5% glycerol. (D) DLS report of BN5C construct refolded in 20 mM Tris pH
8.5, 300 mM NaCl, 5% glycerol. (E) DLS report of BN5C construct refolded in 20 mM Tris pH
8.5, 0 M NaCl, 5% glycerol. (F) DLS report of BN5C construct refolded in 20 mM Tris pH 8.5,
150 mM NaCl, 5% glycerol, 0.1% sodium deoxycholate.
Again, the nanoparticles should be about 25-35 nanometers in diameter if they are
refolded correctly. The first set of conditions did not yield very positive results from the DLS, as
shown in Figure 9. Condition A showed evidence of aggregation and appears to very polydisperse, as there is not much agreement in size. Condition B is still poly-disperse but there is
less aggregation of the protein. The same is true for Condition C while Condition D exhibits both
high aggregation and poly-dispersity. The particles present in Condition E appear to be relatively
uniform in size, but the diameter is slightly smaller than what was expected for this construct.
However, it still shows the best results out of all of the conditions tested in this screen. Condition
F is still poly-disperse and while there is no agreement in size, there doesn’t appear to be much
aggregation. The results from the first screen were taken into account when developing
conditions for the second screen.
A

B

34

C

D

E

F

Figure 10. (A) DLS report of BN5C construct refolded in 20 mM Tris pH 8.5, 0 M NaCl, 5%
glycerol. (B) DLS report of BN5C construct refolded in 20 mM Tris pH 8.5, 0 M NaCl, 5%
glycerol, 0.1% sodium deoxycholate. (C) DLS report of BN5C construct refolded in 20 mM Tris
pH 8.5, 0 M NaCl, 5% glycerol, 0.2% sodium cholate. (D) DLS report of BN5C construct
refolded in 20 mM Tris pH 8.5, 0 M NaCl, 5% glycerol, 0.1% sodium deoxycholate. (E) DLS
report of BN5C construct refolded in 20 mM Tris pH 8.5, 0 M NaCl, 5% glycerol, 0.2% sodium
cholate. (F) DLS report of BN5C construct refolded in 20 mM Tris pH 8.5, 50 mM NaCl, 5%
glycerol.
The results from the first screening showed that the condition with no salt and the
condition with sodium deoxycholate yielded the best results. Thus, the conditions tested for the
second screening all contained low or no salt and/or a detergent such as cholate or deoxycholate.
The results are shown in Figure 10. All of the conditions exhibited a lot of poly-dispersity, with
the exception of Condition A. Conditions A and F were the only samples to not show evidence of
aggregation and both of these conditions contained peaks at a diameter that was smaller than
expected for the BN5C-H1 construct. This could indicate protein that did not fold correctly or
incompletely folded. In general, the results for the second screening were not any more positive
than those of the first screening, despite developing the screen based on the best results from the
previous one. Fifteen different conditions were tested using the BN5C-H1 construct, and none
displayed good refolding according to the DLS results.
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Figure 11. (A) DLS report of S43 construct refolded in 20 mM Tris pH 7.5, 20 mM
(NH4)2HPO4, 5% glycerol. (B) DLS report of S43 construct refolded in 20 mM Tris pH 7.5, 50
mM (NH4)2HPO4, 5% glycerol.
The first test conditions for the S43-9C-2IAd-M2eN construct were buffers that
contained ammonium sulfate. While previous constructs similar to S43 had shown positive
results refolding in ammonium sulfate, the DLS reports generated for these conditions were not
encouraging, as shown in Figure 11. While there is not as much poly-dispersity as was witnessed
with the refolding of the BN5C construct, there seemed to be a high level of aggregation. Similar
to the previous construct, the S43 nanoparticle is expected to have a diameter of around 25-30
nanometers. The peaks shown in Figure 11 are over 50 nanometers for both refolding conditions.
The next step involved screening the refolding of the S43 protein with more conventional
conditions to get a general idea of the refolding properties of the particular construct.
The results of the first screen for the S43 construct (not shown) were not encouraging.
Condition A is both poly-disperse and appears to be highly aggregated. Condition B shows only
the solvent peak, implying that there was no protein present in the sample. This needs to be
further examined using electron microscopy to determine the cause of the lack of particles.
Condition C contains much less aggregation and the peaks are around the diameter that the S43
construct is expected to be, but there is a lot of poly-dispersity, meaning that the particles are not
uniform in size. These results were taken into account when creating the next set of screening
conditions.
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Figure 12. (A) DLS report of S43 construct refolded in 20 mM Tris pH 7.5, 50 mM NaCl, 5%
glycerol, 0.2% sodium cholate. (B) DLS report of S43 construct refolded in 20 mM Tris pH 7.5,
50 mM NaCl, 5% glycerol, 0.1% sodium deoxycholate.
The second screen of the S43 construct contained four different conditions, two of which
are shown in Figure 12. Two of the conditions, which did not contain any detergent, only showed
solvent peaks on the DLS reports and are not shown. It is believed that this may be due to
massive aggregation. The condition which contained sodium cholate, was only slightly polydisperse and peaked around 50 nm, which is slightly higher than the expected size of the
nanoparticles. The condition which contained sodium deoxycholate, was poly-dispersed and
contained peaks in the expected range of the nanoparticle diameter, but also showed signs of
aggregation.

Electron Microscopy
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Figure 13. EM image of the BN5C-M2eN-mh-ch-8r-H1 protein after refolding in 20 mM Tris at
pH 8.5, 150 mM NaCl and 5% glycerol. The particle within the red square is an example of what
a correctly formed nanoparticle might look like under electron microscopy.
Regardless of the results from the DLS report, samples from each of the refolding
conditions performed for the BN5C construct were analyzed with electron microscopy. The EM
images show the nanoparticles, or lack thereof, in the sample and are a more definitive way to
determine if the refolding was successful. An EM image for the first refolding attempt, in 20 mM
Tris pH 8.5, 150 mM NaCl, 5% glycerol, is shown in Figure 13. The red box encloses an
example of a well shaped nanoparticle. The particle is spherical and the black ring around the
particle indicates that the particle has thickness, meaning that the spherical shape exists in three
dimensions. The size of the particle appears to be within the range of 25-35 nanometers that is
expected for the BN5C construct. But although there is evidence of a correctly formed particle,
this refolding event was still not successful. There were very few particles of this nature present
in the EM images for this refolding condition and much of the protein formed small misshaped
particles or strings. Some of the images from this refolding attempt show massive aggregation. A
good refolding condition would contain many correctly formed particles with very little unfolded
protein or aggregates.
The EM images for the first refolding screen, for which the DLS results are shown in
Figure 9, were not any more positive. The images for Condition A show some spherical particles,
but none of them display any thickness. There is also a lot of aggregation visible. The images for
Condition B display mostly misshaped or small particles, again with no thickness, or aggregated
protein. There are a small number of particles that look like they may have formed correctly, but
not enough to consider it a successful refolding. Almost all of the images for Condition C
contain massive aggregation. Again, the images for Condition D contain a lot of aggregation.
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There are a few examples of spherical particles, but they do not appear to have any thickness.
Condition E contains a lot of misshaped particles and protein strands, while Condition F only
contains aggregated protein.
The second set of screening conditions was not any better. Condition A only showed
misshaped strands and particles that did not form correctly. The images for Condition B and
Condition C contained mostly aggregated protein. Images for Condition D did not show any
protein but contained a lot of crystal-like fragments, most likely due to an interaction between
the deoxycholate and the stain used for the electron microscope. The same goes for Condition E
and the cholate. The images for Condition F did not show any nanoparticles, only small
misshaped strands of protein.
The first refolding attempt for the S43-9C-2IAd-M2eN-ch construct was done in a buffer
containing ammonium sulfate. The EM images for the 20 mM condition contain small misshaped
particles that do show evidence of having thickness, but are not spherical nor the size that we
would expect. The 50 mM condition shows more of the same, with very small non-spherical
particles. The first screen of the S43 construct did not show very many particles either. The
images from each of the three conditions all exhibited a lot of protein aggregation, with very few
particles around the expected 30-50 nm size.
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Figure 14. EM image of the S43-9C-2IAd-M2eN construct refolded in 20 mM Tris pH 7.5, 50
mM NaCl, 5% Glycerol, 0.1% Sodium deoxycholate. Several nanoparticles of the correct size
are visible and there is little aggregation or unfolded protein.
The second screen had mixed results. The two conditions that did not contain detergents
displayed only aggregated protein. The third condition, with sodium cholate, had a few
nanoparticles of the correct size but was composed mostly of misshaped protein and aggregation.
The fourth condition from the second screen, containing sodium deoxycholate, is the best in
terms of nanoparticle formation. The EM image for this condition is shown in Figure 14. There
are several examples of nanoparticles with the expected diameter for the S43 construct. There is
still some aggregation and unfolded protein present, but not as much as the other conditions. The
relative success of this condition indicates that deoxycholate could be an important factor in the
refolding of this construct.
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Discussion

The results of the biophysical analysis of the BN5C-H1 construct did not reveal any
promising refolding conditions, despite the number of screens performed. The S43 construct, on
the other hand, showed some success using sodium deoxycholate, though not with any other type
of condition. In general, the refolding of the constructs whose structure contain a tetramer and a
trimer, such as the BN5C and S43 constructs, have not been as successful as structures
containing a pentamer (Neef and Burkhard, unpublished data). It is unclear whether this is more
due to the structure itself, or the relative unfamiliarity with the refolding properties of the
tetramer/trimer combination.
One reason for the lack of nanoparticles observed with the BN5C-H1 construct may have
been the low concentration of protein used for refolding. The bands present on the SDS-PAGE
gels during the latter stages of purification were very faint. After the various rounds of
purification, very little protein was actually obtained, and it had a very low concentration, about
0.05 mg/mL. The fact that the protein was already at such a low concentration made it more
difficult to work with and may have contributed to the poor results seen in the DLS graphs and
EM images. There was little protein present to assemble into nanoparticles, which correlates to
the lack of spherical nanoparticles observed in the EM images of the refolding screens.
Therefore, the lack of nanoparticles could be due to a lack of protein and especially the difficulty
of removing impurities. The BN5C construct was never adequately purified.
This highlights the importance of the his-tag present in the S43 construct. The six
histidines at the end of the sequence made the protein much easier to purify. The binding and
unbinding of the protein to the Nickel column was facilitated by a change in pH and the
protonation of the histidines. This resulted in a more highly concentrated protein following
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purification, as indicated by the band in the SDS-PAGE gel. Since the protein was present at a
high concentration, we were able to use a different refolding technique. The difference was
evident in the amount of protein present in the EM images, whether or not it had correctly
refolded. The ideal result of self-assembly would be many self-assembled nanoparticles with
very little unfolded protein present. Therefore, having a relatively high concentration of protein
is a very important element of refolding. Going forward, the his-tag appears to be an essential
component of creating a nanoparticle influenza vaccine.
The best looking nanoparticles in the EM images are from the S43 construct refolded in
0.1% deoxycholate. Many distinct nanoparticles are present, but there were also signs of
aggregation. The DLS report also showed aggregation and was still fairly poly-disperse. The
purpose of the screen was to identify a condition in which the particles seemed to form best, and
use this data to create a more specific refolding condition. This goal was achieved in that
deoxycholate has been identified as an important component for the refolding of the S43
construct. The assembly of the nanoparticles depends on sustaining the intra-molecular bonds of
the nanoparticle while avoiding inter-nanoparticle bonds, so it is not surprising that a detergent
appears to be an important factor in the refolding of this construct. Using this data, a new set of
conditions can be created based on the inclusion of deoxycholate. There is still a lot of work to
be done to find a specific condition that will allow for the optimal refolding of the S43 construct.
In order to proceed to testing the nanoparticles as a vaccine, the protein must be able to
consistently refold with uniform results.
The S43-9C-2IAd-M2eN construct shows promising results for purifying and refolding
and following further work to find the best possible refolding condition, it could move to the
next stage of developing an avian influenza vaccine. Although the S43 construct has not yet
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shown evidence of efficient and complete refolding, progress has been made to finding the
optimal condition. Depending on the success of subsequent refolding attempts, the next step is to
test the ability of the nanoparticles to elicit an immune response in animal models to determine
the viability of an avian influenza vaccine composed of S43 peptide nanoparticles.
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